ClinicalTrials.gg
RecruitingNCT07215585SOUNDTRACK-D2Updated Oct 9, 2026

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

A Phase 3 interventional study of AZD0486 and R-mini-CHOP in Large B-cell Lymphoma, sponsored by AstraZeneca. Recruiting at 82 sites in 12 countries. Open to participants aged 65 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 9, 2026First site in GermanySite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
65 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Lymphoma, B-Cell by AstraZeneca — 7 open to participants now, 9 under way, 3 of them phase 3. Lymphoma, B-Cell · AstraZeneca.

Planned enrollment
3rd of 13
420 · median 226
Started
2025
with 3 others
Phase 3
3 of 15
2 open now
Registered
13th of 15
by date

Among the 15 studies in Lymphoma, B-Cell by AstraZeneca, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2025, is one of 3 in phase 3, and was the 13th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

7 of the 15 studies in Lymphoma, B-Cell by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 65 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Lymphoma, B-Cell by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.

03

Conditions studied

  • Large B-cell Lymphoma

Browse trials for

Keywords

  • Large B-cell Lymphoma
  • LBCL
  • AZD0486
  • CD3
  • CD19
  • TCE
  • B-cell malignancies
  • Soundtrack-D2
04

Who can participate

Ages eligible
65 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:

  • Participants are either 80 years of age or older, OR 65 to 79 years of age or older and classified as unfit per sGA, and otherwise not considered candidates for full-dose R-CHOP per investigator assessment;
  • confirmed diagnosis of previously untreated LBCL as per WHO-HEM5 (excluding plasmablastic lymphoma) and follicular large cell lymphoma;
  • FDG-avid and as per Lugano and Ann Arbor staging;
  • Stage I bulky (7.5 cm and greater) to Stage IV;
  • performance status 0 to 2;
  • Adequate bone marrow, liver, renal and cardiac function.

The above is a summary, other inclusion criteria details may apply.

  • As judged by the investigator, any evidence of diseases which make it undesirable for the participant to participate in the study, or that would jeopardise compliance with the protocol
  • Diagnosis of post-transplant lymphoproliferative disease, plasmablastic lymphoma, Richter's transformation, prior history of or concurrent indolent lymphoma (including de novo transformed or composite lymphoma).
  • History of CNS involvement by their B-NHL or history of CNS medical condition
  • Known history of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS).
  • Active or uncontrolled infection
  • Major cardiac abnormalities
  • Prior anti-lymphoma therapy except for for symptom control
  • Requires chronic therapy for active /inflammatory condition, with some exceptions

The above is a summary, other exclusion criteria details may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Phase III Arm A: R-mini-CHOP and AZD0486

    2 cycles of R-mini-CHOP followed sequentially by multiple cycles of AZD0486 at RP3D.

    Drug: AZD0486 · Drug: R-mini-CHOP

  • Active comparator
    Phase III Arm B: R-mini-CHOP

    6 cycles of R-mini-CHOP per SoC regimen.

    Drug: R-mini-CHOP

  • Experimental
    Safety Run in: R-mini-CHOP and AZD0486

    2 cycles of R-mini-CHOP followed sequentially by multiple cycles of AZD0486 at RP2D.

    Drug: AZD0486 · Drug: R-mini-CHOP

Interventions

  • Bispecific monoclonal IgG4 antibody

    Also known as: TNB-486

  • DrugR-mini-CHOP

    Intravenous administration: Rituximab 375 mg/m2, Cyclophosphamide 400 mg/m2, Doxorubicin 25 mg/m2, Vincristine 1 mg, and Oral administration: Prednisone 40 mg/m2

06

What researchers measure

Primary outcomes

  1. SRI - Safety evaluation of R-mini-CHOP × 2 followed by AZD0486: Number of participants with treatment-related adverse events.

    Incidence and severity of AEs, SAEs, AESIs, and events of clinical interest based on NCI CTCAE v5.0/ASTCT, vital signs, laboratory parameters.

    Time frame: Up to 1 year

  2. SRI - Tolerability evaluation of R-mini-CHOP × 2 followed by AZD0486: Number of participants with treatment-related adverse events.

    AEs leading to study treatment discontinuation or dose modification based on NCI CTCAE v5.0/ASTCT, vital signs, laboratory parameters.

    Time frame: Up to 1 year

  3. SRI - Determination of the recommended Phase III dose (RP3D)

    The RP3D will be the dose of AZD0486 selected for the Phase 3 part based on safety data compiled during the Safety Run-In part

    Time frame: Up to 1 year

  4. Phase 3 - To demonstrate the superiority of R-mini-CHOP x2 followed by AZD0486 compared to R-mini-CHOP x6 regimen.

    Progression-free Surival (PFS), based on Lugano 2014 Response Criteria.

    Time frame: Up to 7 years

Secondary outcomes

  1. Safety Run-In and Phase 3 - ORR

    ORR defined as the proportion of participants achieving either a PR or CR at timepoints defined in the study protocol, based on Lugano 2014 Response Criteria as determined by Investigator assessment.

    Time frame: Up to 7 years

  2. Safety Run-In and Phase 3 - CR Rate

    CR rate is defined as the proportion of participants achieving a CR at timepoints defined in the study protocol, based on Lugano 2014 Response Criteria as determined by Investigator assessment.

    Time frame: Up to 7 years

  3. Safety Run-In and Phase 3 - DoR

    DoR is defined as the time from the date of first documented response until the date of documented progression based on Lugano 2014 criteria as determined by Investigator assessment or death due to any cause.

    Time frame: Up to 7 years

  4. Safety Run-In and Phase 3 - DoCR

    DoCR is defined as the time from the date of first documented CR until the date of documented progression or death due to any cause, as assessed by the Investigator.

    Time frame: Up to 7 years

  5. Safety Run-In and Phase 3 - PFS

    PFS is defined as the time from date of the first dose to date of documented objective disease progression as per Lugano 2014 or death (by any cause in the absence of progression), as determined by Investigator assessment.

    Time frame: Up to 7 years

  6. Safety Run In and Phase 3 - OS

    OS defined as the time from date of the first dose until death due to any cause.

    Time frame: Up to 7 years

  7. Phase 3 - Time from randomisation to second progression or death (PFS2)

    PFS2 is defined as the time from randomisation to the earliest of the progression event (following the initial investigator-assessed progression), after first subsequent therapy, or death.

    Time frame: Up to 7 years

  8. Phase 3 - Time to First Subsequent Therapy or Death (TFST)

    TFST is defined as time from randomisation until the start date of first subsequent anti-lymphoma therapy after discontinuation of randomised treatment, or death due to any cause.

    Time frame: Up to 7 Years

  9. Phase 3 - Safety evaluation of R-mini-CHOP × 2 followed by AZD0486: Number of participants with treatment-related adverse events.

    Incidence and severity of AEs, SAEs, AESIs, and events of clinical interest based on NCI CTCAE v5.0/ASTCT, vital signs, laboratory parameters.

    Time frame: Up to 7 years

  10. Phase 3 - Tolerability evaluation of R-mini-CHOP × 2 followed by AZD0486: Number of participants with treatment-related adverse events.

    AEs leading to study treatment discontinuation or dose modification based on NCI CTCAE v5.0/ASTCT, vital signs, laboratory parameters.

    Time frame: Up to 7 years

  11. Safety Run-In and Phase 3 - Pharmacokinetics of AZD0486: serum concentration of study drug

    Maximum observed serum concentration of AZD0486.

    Time frame: Up to 7 years

  12. Safety Run-In and Phase 3 - Pharmacokinetics of AZD0486: Maximum plasma concentration of the study drug (Cmax).

    Maximum observed plasma concentration of AZD0486.

    Time frame: Up to 7 years

  13. Safety Run-In and Phase 3 - Pharmacokinetics of AZD0486: Concentration of study drug reached before next dose (Ctrough).

    Observed plasma concentration of AZD0486 right before next dose of AZD0486.

    Time frame: Up to 7 years

  14. Safety Run-In and Phase 3 - To determine the immunogenicity of AZD0486

    Summary of pre-existing and treatment induced ADAs for AZD0486 (positive or negative, titres) and the impact on PK, efficacy or safety.

    Time frame: Up to 7 years

  15. Phase 3 - Safety evaluation of R-mini-CHOP × 2 followed by AZD0486 versus R-mini-CHOP × 6

    Evaluation of key participant-reported side effects (pain, fatigue) and overall treatment tolerability, lymphoma-specific concerns, and HRQoL.

    Time frame: Up to 7 years

  16. Phase 3 - Efficacy evaluation of R-mini-CHOP × 2 followed by AZD0486 versus R-mini-CHOP × 6

    Evaluation of key participant-reported side effects (pain, fatigue) and overall treatment tolerability, lymphoma-specific concerns, and HRQoL.

    Time frame: Up to 7 years

07

Study locations

29 of 82 sites recruiting
  • Research Site
    Clayton, 3168, Australia
    Not yet recruiting
  • Research Site
    Macquarie University, 2109, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Melbourne, 3000, Australia
    Recruiting
  • Research Site
    Nedlands, 6009, Australia
    Not yet recruiting
  • Research Site
    Waratah, 2298, Australia
    Not yet recruiting
  • Research Site
    Antwerp, 2030, Belgium
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Brussels, 1200, Belgium
    Not yet recruiting
  • Research Site
    Ghent, 9000, Belgium
    Recruiting
  • Research Site
    Leuven, 3000, Belgium
    Recruiting
  • Research Site
    Roeselare, 8800, Belgium
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Yvoir, 5530, Belgium
    Recruiting
  • Research Site
    Porto Alegre, 90035-003, Brazil
    Recruiting
  • Research Site
    São Paulo, 05652000, Brazil
    Recruiting
  • Research Site
    Calgary, Alberta T2N 5G2, Canada
    Recruiting
  • Research Site
    Victoria, British Columbia V8R 6V5, Canada
    Not yet recruiting
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Oshawa, Ontario L1G 2B9, Canada
    Not yet recruiting
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
    Not yet recruiting
  • Research Site
    Chicoutimi, Quebec G7H 5H6, Canada
    Not yet recruiting
  • Research Site
    Beijing, 100730, China
    Recruiting
  • Research Site
    Changchun, 130021, China
    Recruiting
  • Research Site
    Chengdu, 610041, China
    Recruiting
  • Research Site
    Chongqing, 400042, China
    Not yet recruiting
  • Research Site
    Fuzhou, 350011, China
    Not yet recruiting
  • Research Site
    Guangzhou, 510060, China
    Recruiting
  • Research Site
    Guangzhou, 510280, China
    Not yet recruiting
  • Research Site
    Guiyang, 550044, China
    Not yet recruiting
  • Research Site
    Haikou, 570311, China
    Not yet recruiting
  • Research Site
    Harbin, 150081, China
    Not yet recruiting
  • Research Site
    Hefei, 230012, China
    Not yet recruiting
  • Research Site
    Jinan, 250117, China
    Recruiting
  • Research Site
    Kunming, 650101, China
    Not yet recruiting
  • Research Site
    Nanchang, 330000, China
    Not yet recruiting
  • Research Site
    Nanning, 530021, China
    Not yet recruiting
  • Research Site
    Nantong, 226001, China
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Shanghai, 200003, China
    Recruiting
  • Research Site
    Shanghai, 20032, China
    Recruiting
  • Research Site
    Shenyang, 110004, China
    Not yet recruiting
  • Research Site
    Wuhan, 430030, China
    Not yet recruiting
  • Research Site
    Xiamen, 361003, China
    Not yet recruiting
  • Research Site
    Berlin, 14165, Germany
    Not yet recruiting
  • Research Site
    Dresden, 01307, Germany
    Not yet recruiting
  • Research Site
    Rostock, 18057, Germany
    Not yet recruiting
  • Research Site
    Hong Kong, 999077, Hong Kong
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Hong Kong, 999077, Hong Kong
    Recruiting
  • Research Site
    Lai Chi Kok, Hong Kong
    Not yet recruiting
  • Research Site
    Akashi, 673-8558, Japan
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Bunkyō City, 113-8677, Japan
    Recruiting
  • Research Site
    Himeji-shi, 670-8540, Japan
    Not yet recruiting
  • Research Site
    Kōtoku, 135-8550, Japan
    Recruiting
  • Research Site
    Kumamoto, 860-8556, Japan
    Not yet recruiting
  • Research Site
    Matsumoto-shi, 399-8701, Japan
    Not yet recruiting
  • Research Site
    Matsuyama, 791-0280, Japan
    Not yet recruiting
  • Research Site
    Meguro-ku, 152-8902, Japan
    Recruiting
  • Research Site
    Nagoya, 460-0001, Japan
    Not yet recruiting
  • Research Site
    Nagoya, 466-8650, Japan
    Not yet recruiting
  • Research Site
    Okayama, 701-1192, Japan
    Not yet recruiting
  • Research Site
    Osaka, 543-8555, Japan
    Not yet recruiting
  • Research Site
    Osaka, 545-8586, Japan
    Recruiting
  • Research Site
    Otaki-Shi, 739-0696, Japan
    Not yet recruiting
  • Research Site
    Sapporo, 003-0804, Japan
    Not yet recruiting
  • Research Site
    Sunto-gun, 411-8777, Japan
    Not yet recruiting
  • Research Site
    Yamagata, 990-9585, Japan
    Recruiting
  • Research Site
    Yokohama, 241-8515, Japan
    Recruiting
  • Research Site
    Kielce, 25-734, Poland
    Not yet recruiting
  • Research Site
    Krakow, 30-727, Poland
    Recruiting
  • Research Site
    Lodz, 93-513, Poland
    Not yet recruiting
  • Research Site
    Lublin, 20-090, Poland
    Not yet recruiting
  • Research Site
    Wroclaw, 50-367, Poland
    Not yet recruiting
  • Research Site
    Seoul, 03080, South Korea
    Recruiting
  • Research Site
    Seoul, 5505, South Korea
    Recruiting
  • Research Site
    Ankara, 06620, Turkey (Türkiye)
    Recruiting
  • Research Site
    Antalya, 07025, Turkey (Türkiye)
    Recruiting
  • Research Site
    Istanbul, 34214, Turkey (Türkiye)
    Not yet recruiting
  • Research Site
    Izmir, 35040, Turkey (Türkiye)
    Not yet recruiting
  • Research Site
    Kocaeli, 41380, Turkey (Türkiye)
    Not yet recruiting
  • Research Site
    Glasgow, Scotland, G12 0YN, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    London, NW1 2PG, United Kingdom
    Recruiting
  • Research Site
    Manchester, M20 4BX, United Kingdom
    Not yet recruiting
  • Research Site
    Newcastle upon Tyne, NE7 7AF, United Kingdom
    Recruiting
  • Research Site
    Nottingham, NG5 1PB, United Kingdom
    Withdrawn

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jun 2030, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2025
First posted
Oct 10, 2025
StartActual
Nov 11, 2025
Primary completionEst.
Jun 10, 2030
CompletionEst.
Jul 29, 2033
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
15 sites added, 1 site removed — first site in Germany. 7 sites changed recruiting status (6 now withdrawn, 1 now recruiting)
Show 7 sites
  • Research Site · Roeselare, BelgiumSuspended→Withdrawn
  • Research Site · Hamilton, CanadaNot yet recruiting→Withdrawn
  • Research Site · Hong Kong, Hong KongRecruiting→Withdrawn
  • Research Site · Akashi, JapanNot yet recruiting→Withdrawn
  • Research Site · Meguro-ku, JapanNot yet recruiting→Recruiting
  • Research Site · Glasgow, Scotland, United KingdomNot yet recruiting→Withdrawn
  • Research Site · Nottingham, United KingdomNot yet recruiting→Withdrawn
Show 15 added (3 Canada, 3 China, 3 Germany, 3 Turkey (Türkiye), 1 Hong Kong, 1 Japan, 1 United Kingdom)
  • Research Site · Oshawa, Canada
  • Research Site · Toronto, Canada
  • Research Site · Chicoutimi, Canada
  • Research Site · Guiyang, China
  • Research Site · Harbin, China
  • Research Site · Shenyang, China
  • Research Site · Berlin, Germany
  • Research Site · Dresden, Germany
  • Research Site · Rostock, Germany
  • Research Site · Hong Kong, Hong Kong
  • Research Site · Nagoya, Japan
  • Research Site · Istanbul, Turkey (Türkiye)
  • Research Site · Izmir, Turkey (Türkiye)
  • Research Site · Kocaeli, Turkey (Türkiye)
  • Research Site · Manchester, United Kingdom
Show 1 removed
  • Research Site · Shatin, Hong Kong
Oct 9, 2026
Study completion
Jul 28, 2033→Jul 29, 2033
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    15 sites added, 1 site removed — first site in Germany. 7 sites changed recruiting status (6 now withdrawn, 1 now recruiting)
    Show 7 sites
    • Research Site · Roeselare, BelgiumSuspended→Withdrawn
    • Research Site · Hamilton, CanadaNot yet recruiting→Withdrawn
    • Research Site · Hong Kong, Hong KongRecruiting→Withdrawn
    • Research Site · Akashi, JapanNot yet recruiting→Withdrawn
    • Research Site · Meguro-ku, JapanNot yet recruiting→Recruiting
    • Research Site · Glasgow, Scotland, United KingdomNot yet recruiting→Withdrawn
    • Research Site · Nottingham, United KingdomNot yet recruiting→Withdrawn
    Show 15 added (3 Canada, 3 China, 3 Germany, 3 Turkey (Türkiye), 1 Hong Kong, 1 Japan, 1 United Kingdom)
    • Research Site · Oshawa, Canada
    • Research Site · Toronto, Canada
    • Research Site · Chicoutimi, Canada
    • Research Site · Guiyang, China
    • Research Site · Harbin, China
    • Research Site · Shenyang, China
    • Research Site · Berlin, Germany
    • Research Site · Dresden, Germany
    • Research Site · Rostock, Germany
    • Research Site · Hong Kong, Hong Kong
    • Research Site · Nagoya, Japan
    • Research Site · Istanbul, Turkey (Türkiye)
    • Research Site · Izmir, Turkey (Türkiye)
    • Research Site · Kocaeli, Turkey (Türkiye)
    • Research Site · Manchester, United Kingdom
    Show 1 removed
    • Research Site · Shatin, Hong Kong
    Study completion Jul 28, 2033→Jul 29, 2033
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07215585
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 10, 2025
Start date
Nov 11, 2025
Primary completion
Jun 10, 2030 (estimated)
Completion
Jul 29, 2033 (estimated)
Last update
Oct 9, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479
Michael Dickinson,, MBBS BS DMSc
principal investigator · Peter MacCallum Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Surovatamig

Start the discussion